Zanamivir

Revision as of 15:08, 8 December 2010 by David Canner (Talk | contribs)

Neuraminidase Inhibitor Pharmacokinetics^[1]^[2]
Parameter	Ritonavir	Oseltamivir
T_max (hr)	1.25	1.5
C_max (ng/ml)	31.6	57
Bioavailability (%)	2	75
Protein Binding (%)	10	42
T_1/2 (hr)	3	3.2
AUC (ng/ml/hr)	185	204
Clearance (L/h)	54.1	18.8
Dosage (mg)	10	300
Metabolism	None	Hepatic

↑ A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009
↑ Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. Epub 2003 Aug 9. PMID:12910331 doi:http://dx.doi.org/10.1007/s00228-003-0639-6

Proteopedia Page Contributors and Editors (what is this?)